Cited by 871Sepsis Diagnosis and TreatmentAutoimmune and Inflammatory Disorders ResearchInflammation biomarkers and pathways

The DOI matches its Crossref record; 47 of the 48 references it cites were found in a registry or an index.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Open access

Shakoory, Bita, Carcillo, Joseph A., Chatham, W. Winn, Amdur, Richard L., Zhao, Huaqing, Dinarello, Charles A., Cron, Randall Q., Opal, Steven M.·2016·Critical Care Medicine

DOI 10.1097/ccm.0000000000001402PMC PMC5378312

Open this paper in CoChat — free account

Abstract

OBJECTIVE: To determine the efficacy of anakinra (recombinant interleukin-1 receptor antagonist) in improving 28-day survival in sepsis patients with features of macrophage activation syndrome. Despite equivocal results in sepsis trials, anakinra is effective in treating macrophage activation syndrome, a similar entity with fever, disseminated intravascular coagulation, hepatobiliary dysfunction, cytopenias, and hyperferritinemia. Hence, sepsis patients with macrophage activation syndrome features may benefit from interleukin-1 receptor blockade. DESIGN: Reanalysis of deidentified data from the phase III randomized interleukin-1 receptor antagonist trial in severe sepsis. SETTING: Multicenter study recruiting through 91 centers from 11 countries in Europe and North America. PATIENTS: Sepsis patients with multiorgan dysfunction syndrome and/or shock (original study) were regrouped based on the presence or the absence of concurrent hepatobiliary dysfunction and disseminated intravascular coagulation as features of macrophage activation syndrome. The non-hepatobiliary dysfunction/disseminated intravascular coagulation group included patients with only hepatobiliary dysfunction, only disseminated intravascular coagulation, or neither. INTERVENTION: Treatment with anakinra or placebo. MEASUREMENTS AND MAIN RESULTS: Main outcome was 28-day mortality. Descriptive and comparative statistics were performed. Data were available for 763 adults from the original study cohort, randomized to receive either anakinra or placebo. Concurrent hepatobiliary dysfunction/disseminated intravascular coagulation was noted in 43 patients (5.6% of total; 18-75 years old; 47% women). The 28-day survival was similar in both anakinra and placebo-treated non-hepatobiliary dysfunction/disseminated intravascular coagulation patients (71.4% vs 70.8%; p = 0.88). Treatment with anakinra was associated with significant improvement in the 28-day survival rate in hepatobiliary dysfunction/disseminated intravascular coagulation patients (65.4% anakinra vs 35.3% placebo), with hazard ratio for death 0.28 (0.11-0.71; p = 0.0071) for the treatment group in Cox regression. CONCLUSIONS: In this subgroup analysis, interleukin-1 receptor blockade was associated with significant improvement in survival of patients with sepsis and concurrent hepatobiliary dysfunction/disseminated intravascular coagulation. A prospective randomized trial using features of macrophage activation syndrome for mortality risk stratification should be undertaken to confirm the role of interleukin-1 blockage.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1097/ccm.0000000000001402

Cites

47 of 47 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference
Levy, M. M., Fink, M. P., Marshall, J. C., Abraham, E. H., Angus, D. C., Cook, D., Cohen, J., Opal, S. M., Vincent, J., & Ramsay, G. (2003) · Critical Care Medicine · doi:10.1097/01.ccm.0000050454.01978.3b · Cited by 5,976
Self-citation
The Pathophysiology and Treatment of Sepsis
Hotchkiss, R. S., & Karl, I. E. (2003) · New England Journal of Medicine · doi:10.1056/nejmra021333 · Cited by 4,132
An Expanded Definition of the Adult Respiratory Distress Syndrome
Murray, J. F., Matthay, M. A., Luce, J. M., & Flick, M. R. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/138.3.720 · Cited by 2,641
Interleukin-1 in the pathogenesis and treatment of inflammatory diseases
Dinarello, C. A. (2011) · Blood · doi:10.1182/blood-2010-07-273417 · Cited by 2,248
Self-citation
Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases
Dinarello, C. A., Simon, A., & van der Meer, J. W. M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3800 · Cited by 1,810
Self-citation
Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome
Fardet, L., Galicier, L., Lambotte, O., Marzac, C., Aumont, C., Chahwan, D., Coppo, P., & Hejblum, G. (2014) · Arthritis & Rheumatology · doi:10.1002/art.38690 · Cited by 1,508
Interleukin-1 and the Pathogenesis of the Acute-Phase Response
Epstein, F. H., & Dinarello, C. A. (1984) · New England Journal of Medicine · doi:10.1056/nejm198411293112205 · Cited by 1,151
Self-citation
Confirmatory interleukin-1 receptor antagonist trial in severe sepsis
Opal, S. M., Fisher, C. J., Dhainaut, J.-F., Vincent, J., Brase, R., Lowry, S. F., SADOFF, J. C., Slotman, G. J., Levy, H. A., BALK, R. A., et al. (1997) · Critical Care Medicine · doi:10.1097/00003246-199707000-00010 · Cited by 882
Self-citation
Recombinant Human Interleukin 1 Receptor Antagonist in the Treatment of Patients With Sepsis Syndrome: Results From a Randomized, Double-blind, Placebo-Controlled Trial
Fisher, C. J. (1994) · JAMA · doi:10.1001/jama.1994.03510470040032 · Cited by 790
Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis
Allen, C. E., Yu, X., Kozinetz, C. A., & McClain, K. L. (2007) · Pediatric Blood & Cancer · doi:10.1002/pbc.21423 · Cited by 637

Show all 48 references

Research works printed but not linked: 4

Emmenegger, 2005, Swiss Med Wkly, 135, 299
Behrens, 2007, J Rheumatol, 34, 1133
Behrens, 2006, J Rheumatol, 33, 2081
Marti-Carvajal, 2012, Cochrane Database Syst Rev, 12, CD004388

Sorted by citations

Items 301–400 of 871

Tocilizumab in hospitalized patients with COVID‐19: Clinical outcomes, inflammatory marker kinetics, and safety
Hill, J. A., Menon, M. P., Dhanireddy, S., Wurfel, M. M., Green, M., Jain, R., Chan, J. D., Huang, J., Bethune, D., Turtle, C. J., et al. (2020) · Journal of Medical Virology · doi:10.1002/jmv.26674 · Cited by 33
Repurposing of Biologic and Targeted Synthetic Anti-Rheumatic Drugs in COVID-19 and Hyper-Inflammation: A Comprehensive Review of Available and Emerging Evidence at the Peak of the Pandemic
Cavalli, G., Farina, N., Campochiaro, C., Luca, G. D. D., Della‐Torre, E., Tomelleri, A., & Dagna, L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.598308 · Cited by 35
The role of influenza A virus-induced hypercytokinemia
Wei, F., Gao, C., & Wang, Y. (2021) · Critical Reviews in Microbiology · doi:10.1080/1040841x.2021.1960482 · Cited by 34
Simultaneous Targeting of IL-1–Signaling and IL-6–Trans-Signaling Preserves Human Pulmonary Endothelial Barrier Function During a Cytokine Storm—Brief Report
Colás-Algora, N., Muñoz-Pinillos, P., Cacho-Navas, C., Ortiz, J. A., de Rivas, G., Barroso, S., López‐Collazo, E., & Millán, J. (2023) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.123.319695 · Cited by 33
The critical impacts of cytokine storms in respiratory disorders
Tramboo, S. R., Elkhalifa, A. M. E., Khursheed, S. Q., Ali, S. I., Shah, N. N., Taifa, S., Rakhshan, R., Shah, I. H., Mir, M. A., Malik, M., et al. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e29769 · Cited by 32
Balanced control of both hyper and hypo-inflammatory phases as a new treatment paradigm in sepsis
Tsirigotis, P. D., Chondropoulos, S. D., Gkirkas, K., Meletiadis, J., & Dimopoulou, I. (2016) · Journal of Thoracic Disease · doi:10.21037/jtd.2016.03.47 · Cited by 33
Hypofibrinogenemia Is Associated With Poor Outcome and Secondary Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome in Pediatric Severe Sepsis*
Signoff, J. K., Fitzgerald, J. C., Teachey, D. T., Balamuth, F., & Weiss, S. L. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001507 · Cited by 34
Anakinra in the treatment of protracted paradoxical inflammatory reactions in HIV-associated tuberculosis in the United Kingdom: a report of two cases
Keeley, A. J., Parkash, V., Tunbridge, A. J., Greig, J. M., Collini, P., McKane, W. S., & Tattersall, R. S. (2020) · International Journal of STD & AIDS · doi:10.1177/0956462420915394 · Cited by 33
Coronavirus disease 2019: investigational therapies in the prevention and treatment of hyperinflammation
Amigues, I., Pearlman, A. H., Patel, A. M., Reid, P. D., Robinson, P. C., Sinha, R. R., Kim, A. H. J., Youngstein, T., Jayatilleke, A., & Konig, M. F. (2020) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2021.1847084 · Cited by 33
Biologic Drugs for Rheumatoid Arthritis in the Context of Biosimilars, Genetics, Epigenetics and COVID-19 Treatment
Bonek, K., Roszkowski, L., Massalska, M., Maśliński, W., & Ciechomska, M. (2021) · Cells · doi:10.3390/cells10020323 · Cited by 33
COVID-19 Infection and Circulating Microparticles—Reviewing Evidence as Microthrombogenic Risk Factor for Cerebral Small Vessel Disease
Nassir, C. M. N. C. M., Hashim, S., Wong, K. K., Halim, S. A., Idris, N. S., Jayabalan, N., Guo, D., & Mustapha, M. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02457-z · Cited by 34
Network Pharmacology Reveals That Resveratrol Can Alleviate COVID-19-Related Hyperinflammation
Xiao, Z., Ye, Q., Duan, X., & Xiang, T. (2021) · Disease Markers · doi:10.1155/2021/4129993 · Cited by 34
Future of sepsis therapies
van der Poll, T. (2016) · Critical Care · doi:10.1186/s13054-016-1274-9 · Cited by 32
The Multiple Organ Dysfunction Syndrome: Syndrome, Metaphor, and Unsolved Clinical Challenge
Marshall, J. C., & Deutschman, C. S. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005139 · Cited by 32
Exploring the Role of Immune System and Inflammatory Cytokines in SARS-CoV-2 Induced Lung Disease: A Narrative Review
Tirelli, C., AMICI, M. D., Albrici, C., Mira, S., Nalesso, G., Re, B., Corsico, A. G., Mondoni, M., & Centanni, S. (2023) · Biology · doi:10.3390/biology12020177 · Cited by 35
Interferon-gamma driven elevation of CXCL9: a new sepsis endotype independently associated with mortality
Giamarellos‐Bourboulis, E. J., Antonelli, M. M., Bloos, F., Kotsamidi, I., Psarrakis, C., Dakou, K., Thomas-Rüddel, D. O., Montini, L. M., Briegel, J., Damoraki, G., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105414 · Cited by 32
Hemophagocytic lymphohistiocytosis in an adult kidney transplant recipient successfully treated by plasmapheresis
Nußhag, C., Morath, C. P., Zeier, M. G., Weigand, M. A., Merle, U., & Brenner, T. (2017) · Medicine · doi:10.1097/md.0000000000009283 · Cited by 32
Comparison of host immune responses to LPS in human using an immune profiling panel, in vivo endotoxemia versus ex vivo stimulation
Tawfik, D. M., Lankelma, J. M., Vachot, L., Cerrato, E., Pachot, A., Wiersinga, W. J., & Textoris, J. (2020) · Scientific Reports · doi:10.1038/s41598-020-66695-2 · Cited by 35
Mucin signature as a potential tool to predict susceptibility to COVID‐19
Bose, M., Mitra, B., & Mukherjee, P. (2020) · Physiological Reports · doi:10.14814/phy2.14701 · Cited by 32
Familial hypercholesterolaemia and COVID-19: A two-hit scenario for endothelial dysfunction amenable to treatment
Vuorio, A. F., Raal, F. J., Kaste, M., & Kovanen, P. T. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.01.021 · Cited by 32
A TLR7 antagonist restricts interferon-dependent and -independent immunopathology in a mouse model of severe influenza
Rappe, J. C. F., Finsterbusch, K., Crotta, S., Mack, M., Priestnall, S. L., & Wack, A. (2021) · The Journal of Experimental Medicine · doi:10.1084/jem.20201631 · Cited by 36
Hepatobiliary Dysfunction and Disseminated Intravascular Coagulation Increase Risk of Mortality in Pediatric Hemophagocytic Lymphohistiocytosis*
Goldman, J. R., Desai, M. S., McClain, K. L., Tcharmtchi, M. H., Kennedy, C. E., Thompson, K., Lam, F. W., Bashir, D. A., Chinn, I. K., Goldberg, B. R., et al. (2018) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000001684 · Cited by 31
Management of Osteoarthritis During the COVID‐19 Pandemic
Ragni, E., Mangiavini, L., Viganò, M., Brini, A. T., Peretti, G. M., Banfi, G., & de Girolamo, L. (2020) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1910 · Cited by 31
American College of Rheumatology Guidance for the Management of Pediatric Rheumatic Disease During the COVID‐19 Pandemic: Version 1
Wahezi, D. M., Lo, M. S., Rubinstein, T. B., Ringold, S., Ardoin, S. P., Downes, K. J., Jones, K. B., Laxer, R. M., Madan, R. P., Mudano, A. S., et al. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41455 · Cited by 31
Severe COVID-19: Immunosuppression or Hyperinflammation?
Liu, Y., Li, Y., Xu, D., Zhang, J., & Peng, Z. (2021) · Shock · doi:10.1097/shk.0000000000001724 · Cited by 33
Nucleic Acid-Sensing Pathways During SARS-CoV-2 Infection: Expectations versus Reality
Mdkhana, B., Sharif‐Askari, N. S., Ramakrishnan, R. K., Goel, S., Hamid, Q. A., & Halwani, R. (2021) · Journal of Inflammation Research · doi:10.2147/jir.s277716 · Cited by 31
The Multifaceted Immunology of Cytokine Storm Syndrome
Lee, P. Y., & Cron, R. Q. (2023) · The Journal of Immunology · doi:10.4049/jimmunol.2200808 · Cited by 33
Self-citation
Tratamiento farmacológico de la COVID-19: revisión narrativa de los Grupos de Trabajo de Enfermedades Infecciosas y Sepsis (GTEIS) y del Grupo de Trabajo de Transfusiones Hemoderivados (GTTH)
Dı́az, E., Menéndez, R. A., Vidal, P., Escapa, M. G., Suberviola, B., Serrano, A., Marcos-Neira, P., Quintana‐Díaz, M., & González, M. C. (2020) · Medicina Intensiva · doi:10.1016/j.medin.2020.06.017 · Cited by 34
Hyperinflammation and the utility of immunomodulatory medications in children with COVID-19
Tanner, T., & Wahezi, D. M. (2020) · Paediatric Respiratory Reviews · doi:10.1016/j.prrv.2020.07.003 · Cited by 30
ESCAPE: An Open-Label Trial of Personalized Immunotherapy in Critically lll COVID-19 Patients
Karakike, E., Dalekos, G. Ν., Koutsodimitropoulos, I., Saridaki, M., Pourzitaki, C., Παπαθανάκος, Γ., Kotsaki, A., Chalvatzis, S., Dimakopoulou, V., Vechlidis, N., et al. (2021) · Journal of Innate Immunity · doi:10.1159/000519090 · Cited by 31
The double sides of NLRP3 inflammasome activation in sepsis
Vigneron, C., Py, B. F., Monneret, G., & Venet, F. (2023) · Clinical Science · doi:10.1042/cs20220556 · Cited by 34
COVID-19 multidisciplinary high dependency unit: the Milan model
Aliberti, S., Amati, F., Pappalettera, M., Pasquale, M. D., D’Adda, A., Mantero, M., Gramegna, A., Simonetta, E., Oneta, A. M., Privitera, E., et al. (2020) · Respiratory Research · doi:10.1186/s12931-020-01516-8 · Cited by 26
Elevated ferritin, mediated by IL-18 is associated with systemic inflammation and mortality in acute respiratory distress syndrome (ARDS)
Mehta, P., Samanta, R. J., Wick, K. D., Coll, R. C., Mawhinney, T. J., McAleavey, P. G., Boyle, A. J., Conlon, J., Shankar‐Hari, M., Rogers, A. J., et al. (2023) · Thorax · doi:10.1136/thorax-2023-220292 · Cited by 29
Review of the Predictive Value of Biomarkers in Sepsis Mortality
Zhang, N., Liu, Y., Yang, C., & Li, X. (2024) · Emergency Medicine International · doi:10.1155/2024/2715606 · Cited by 29
COVID-19: the new challenge for rheumatologists
Belov, B. S., & Karateev, A. E. (2020) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2020-2-110-116 · Cited by 29
“Cytokine storm”, not only in COVID-19 patients. Mini-review
Lukán, N. (2020) · Immunology Letters · doi:10.1016/j.imlet.2020.09.007 · Cited by 29
Sepsis in the critically ill patient: current and emerging management strategies
Heming, N., Azabou, É., Cazaumayou, X., Moine, P., & Annane, D. (2020) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2021.1846522 · Cited by 32
Existing Drugs Considered as Promising in COVID-19 Therapy
Janik, E., Niemcewicz, M., Podogrocki, M., Saluk, J., & Bijak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115434 · Cited by 28
High-CBD Extract (CBD-X) Downregulates Cytokine Storm Systemically and Locally in Inflamed Lungs
Aswad, M., Hamza, H., Pechkovsky, A., Zikrach, A., Popov, T., Zohar, Y., Shahar, E., & Louria‐Hayon, I. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.875546 · Cited by 30
Cannabinoid WIN55,212-2 reprograms monocytes and macrophages to inhibit LPS-induced inflammation
Pérez‐Diego, M., Angelina, A., Martín‐Cruz, L., de la Rocha‐Muñoz, A., Maldonado, A. E., Sevilla‐Ortega, C., & Palomares, Ó. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1147520 · Cited by 29
Immunomodulatory drugs in sepsis: a systematic review and meta‐analysis
Robey, R. C., Logue, C., Caird, C. A., Hansel, J., Hellyer, T. P., Simpson, J. A., Dark, P. M., Mathioudakis, A. G., & Felton, T. (2024) · Anaesthesia · doi:10.1111/anae.16263 · Cited by 35
Pathogenesis of Hemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome: A Case Report and Review of the Literature
Gioia, C., Paroli, M., Izzo, R., Sanzo, L. D., Rossi, E. M. C., Pignatelli, P., & Accapezzato, D. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115921 · Cited by 33
Cytokine Storm and Sepsis-Induced Multiple Organ Dysfunction Syndrome
Carcillo, J. A., & Shakoory, B. (2024) · Advances in experimental medicine and biology · doi:10.1007/978-3-031-59815-9_30 · Cited by 28
Self-citation
Progress in cytokine research for ARDS: A comprehensive review
Zhou, K., & Lu, J. (2024) · Open Medicine · doi:10.1515/med-2024-1076 · Cited by 32
Sepsis subphenotypes: bridging the gaps in sepsis treatment strategies
Zhang, X., Zhang, W., Zhang, H., & Liao, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546474 · Cited by 30
Pharmacological management of COVID-19 patients with ARDS (CARDS): A narrative review
Matera, M. G., Rogliani, P., Calzetta, L., & Cazzola, M. (2020) · Respiratory Medicine · doi:10.1016/j.rmed.2020.106114 · Cited by 29
Recent findings on the Coronavirus disease 2019 (COVID-19); immunopathogenesis and immunotherapeutics
Ebrahimi, N., Aslani, S., Babaie, F., Hemmatzadeh, M., Hosseinzadeh, R., Joneidi, Z., Tourzani, Z. M., Pakravan, N., & Mohammadi, H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.107082 · Cited by 28
Infliximab and Intravenous Gammaglobulin in Hospitalized Severe COVID-19 Patients in Intensive Care Unit
Farrokhpour, M., Rezaie, N., Moradi, N., Rad, F. G., Izadi, S., Azimi, M., Zamani, F., Izadi, S., Ranjbar, M., Makiani, M. J., et al. (2021) · Archives of Iranian Medicine · doi:10.34172/aim.2021.22 · Cited by 28
The potential role of Fluoroquinolones in the management of Covid-19 a rapid review
Damanhouri, Z. A., Alkreathy, H. M., Ali, A. S., & Karim, S. (2021) · Journal Of Advanced Pharmacy Education And Research · doi:10.51847/fe1ioiptwd · Cited by 28
Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics
Kumar, S., Çalışkan, D. M., Janowski, J., Faist, A., Conrad, B. C. G., Lange, J., Ludwig, S., & Brunotte, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.752227 · Cited by 28
IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6
Nasonov, E. L. (2020) · Rheumatology Science and Practice · doi:10.14412/1995-4484-2020-245-261 · Cited by 29
Immune Profiling Panel: A Proof-of-Concept Study of a New Multiplex Molecular Tool to Assess the Immune Status of Critically Ill Patients
Tawfik, D. M., Vachot, L., Bocquet, A., Venet, F., Rimmelé, T., Monneret, G., Blein, S., Montgomery, J., Hemmert, A., Pachot, A., et al. (2020) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiaa248 · Cited by 28
Whole blood transcriptomics identifies subclasses of pediatric septic shock
Yang, J. O., Zinter, M. S., Pellegrini, M. A., Wong, M. Y., Gala, K. P., Markovic, D., Nadel, B. B., Peng, K., Do, N., Mangul, S., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04689-y · Cited by 28
Interleukin-6 related signaling pathways as the intersection between chronic diseases and sepsis
Yang, J., Yang, L., Wang, Y., Huai, L. F., Shi, B., Zhang, D., Xu, W., & Cui, D. (2025) · Molecular Medicine · doi:10.1186/s10020-025-01089-6 · Cited by 28
COVID‐19 und Immunregulation – von grundlegenden und translationalen Aspekten zu klinischen Implikationen
Schön, M. P., Berking, C., Biedermann, T., Buhl, T., Erpenbeck, L., Eyerich, K., Eyerich, S., Ghoreschi, K., Goebeler, M., Ludwig, R. J., et al. (2020) · JDDG Journal der Deutschen Dermatologischen Gesellschaft · doi:10.1111/ddg.14169_g · Cited by 28
Statins as Adjuvant Therapy for COVID-19 to Calm the Stormy Immunothrombosis and Beyond
Vuorio, A. F., & Kovanen, P. T. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.579548 · Cited by 28
The Rheumatology Drugs for COVID-19 Management: Which and When?
Atzeni, F., Masala, I. F., Rodríguez‐Carrio, J., Garcés, R. R., Gerratana, E., Corte, L. L., Giallanza, M., Nucera, V., Riva, A., Espinosa, G., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10040783 · Cited by 28
Macrophage-preferable delivery of the leucine-rich repeat domain of NLRX1 ameliorates lethal sepsis by regulating NF-κB and inflammasome signaling activation
Koo, J., Kim, S. H., Jeon, S.-H., Kang, M., & Choi, J. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.120845 · Cited by 27
Efficacy and Safety of Anakinra Plus Standard of Care for Patients With Severe COVID-19
Fanlo, P., Gracia-Tello, B., Aizpuru, E. F., Troncoso, J. Á., García, A. G., Prieto‐González, S., Freire, M., Argibay, A. B., Pallarés, L., Todolí, J., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.7243 · Cited by 27
Anakinra after treatment with corticosteroids alone or with tocilizumab in patients with severe COVID‑19 pneumonia and moderate hyperinflammation. A retrospective cohort study: reply
Millán, I. F. A., Salvatierra, J., & Hernández‐Quero, J. (2021) · Internal and Emergency Medicine · doi:10.1007/s11739-021-02690-3 · Cited by 27
Recent advances of precision immunotherapy in sepsis
Arapis, A., Panagiotopoulos, D., & Giamarellos‐Bourboulis, E. J. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf001 · Cited by 26
DNA Viremia Is Associated with Hyperferritinemia in Pediatric Sepsis
Simon, D. W., Halstead, E. S., Davila, S., Kernan, K. F., Clark, R. S. B., Storch, G. A., & Carcillo, J. A. (2019) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2019.06.033 · Cited by 27
Self-citation
A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial
Hinks, T., Barber, V. S., Black, J., Dutton, S., Jabeen, M., Melhorn, J., Rahman, N. M., Richards, D. B., Lasserson, D. S., Pavord, I. D., et al. (2020) · Trials · doi:10.1186/s13063-020-04593-8 · Cited by 25
Hyperferritinemic sepsis, macrophage activation syndrome, and mortality in a pediatric research network: a causal inference analysis
Fan, Z., Kernan, K. F., Qin, Y., Canna, S., Berg, R. A., WESSEL, D. L., Pollack, M. M., Meert, K. L., Hall, M. W., Newth, C. J. L., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04628-x · Cited by 26
Self-citation
Small Immunomodulatory Molecules as Potential Therapeutics in Experimental Murine Models of Acute Lung Injury (ALI)/Acute Respiratory Distress Syndrome (ARDS)
Shah, D., Das, P., Acharya, S., Agarwal, B., Christensen, D. J., Robertson, S. M., & Bhandari, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22052573 · Cited by 26
Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis/macrophage activation syndrome: A systematic review
Charlesworth, J. E. G., & Kavirayani, A. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14029 · Cited by 25
Diagnosis, Treatment, and Management of Hemophagocytic Lymphohistiocytosis in the Critical Care Unit
Hines, M., Bhatt, N. S., & Talano, J. (2019) · Springer eBooks · doi:10.1007/978-3-030-01322-6_9 · Cited by 25
Systemic Complications of COVID-19
Ashraf, O., Young, M., Malik, K. J., & Cheema, T. J. (2020) · Critical Care Nursing Quarterly · doi:10.1097/cnq.0000000000000324 · Cited by 24
COVID-19 in Association With Development, Course, and Treatment of Systemic Autoimmune Rheumatic Diseases
Lakota, K., Pirkmajer, K. P., Hočevar, A., Sodin‐Šemrl, S., Rotar, Ž., Čučnik, S., & Žigon, P. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2020.611318 · Cited by 26
COVID-19 and Disease-Modifying Anti-rheumatic Drugs
D’Silva, K. M., & Wallace, Z. S. (2021) · Current Rheumatology Reports · doi:10.1007/s11926-021-00998-9 · Cited by 25
Identification of Clinical Phenotypes in Septic Patients Presenting With Hypotension or Elevated Lactate
Aldewereld, Z., Zhang, L. A., Urbano, A., Parker, R. S., Swigon, D., Banerjee, I., Gómez, H., & Clermont, G. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.794423 · Cited by 26
IL‐1B rs16944 polymorphism is related to septic shock and death
Jiménez‐Sousa, M. Á., Medrano, L. M., Liu, P., Almansa, R., Fernández‐Rodríguez, A., Gómez‐Sánchez, E., Rico, L., Heredia‐Rodríguez, M., Gómez‐Pesquera, E., Tamayo, E., et al. (2016) · European Journal of Clinical Investigation · doi:10.1111/eci.12702 · Cited by 25
Prescribing motivations and patients’ characteristics related to the use of biologic drugs in adult-onset Still’s disease: analysis of a multicentre “real-life” cohort
Ruscitti, P., Cipriani, P., Liakouli, V., Iacono, D., Pantano, I., Caso, F., Perosa, F., Atzeni, F., Cantatore, F. P., Scarpa, R., et al. (2019) · Rheumatology International · doi:10.1007/s00296-019-04358-w · Cited by 25
Immunotherapy in the context of sepsis-induced immunological dysregulation
Wu, Y., Wang, L., Li, Y., Cao, Y., Wang, M., Deng, Z., & Kang, H. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1391395 · Cited by 27
Current perspectives in the management of sepsis and septic shock
Chiscano‐Camón, L., Ruiz‐Sanmartín, A., Bajaña, I., Bastidas, J., López‐Martínez, R., Franco‐Jarava, C., González‐López, J. J., Larrosa, N., Riera, J., Nuvials, X., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1431791 · Cited by 30
Sepsis-Induced Cardiomyopathy and Cardiac Arrhythmias: Pathophysiology and Implications for Novel Therapeutic Approaches
Pamporis, K., Karakasis, P., Pantelidaki, A., Goutis, P. A., Grigoriou, K., Theofilis, P., Katsaouni, A., Botis, M., Karanikola, A.-E., Milaras, N., et al. (2025) · Biomedicines · doi:10.3390/biomedicines13112643 · Cited by 27
Immune Modulation in Pediatric Sepsis
Hall, M. (2019) · Journal of Pediatric Intensive Care · doi:10.1055/s-0038-1676607 · Cited by 24
Repurposing Existing Drugs for the Treatment of COVID-19
Farne, H. A., Kumar, K., Ritchie, A. I., Finney, L., Johnston, S. L., & Singanayagam, A. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-566fr · Cited by 24
Off-label use of anti-IL-1 drugs in rheumatic diseases
Stefania, S., Colìa, R., Rotondo, C., Corrado, A., & Cantatore, F. P. (2021) · International Journal of Immunopathology and Pharmacology · doi:10.1177/20587384211006584 · Cited by 24
SARS-CoV-2 Myocarditis: Insights Into Incidence, Prognosis, and Therapeutic Implications
Hassan, O. K. A., Sheng, C. C., Wang, T. K. M., & Cremer, P. C. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01551-x · Cited by 27
Methods for Phenotyping Adult Patients in Sepsis and Septic Shock: A Scoping Review
Li, H. J., Markal, A., Balch, J. A., Loftus, T. J., Efron, P. A., Ozrazgat‐Baslanti, T., & Bihorac, A. (2022) · Critical Care Explorations · doi:10.1097/cce.0000000000000672 · Cited by 24
Gaps and opportunities in sepsis translational research
Marshall, J. C., & Leligdowicz, A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104387 · Cited by 28
The Role of Inflammatory Cytokines (Interleukin-1 and Interleukin-6) as a Potential Biomarker in the Different Stages of COVID-19 (Mild, Severe, and Critical)
Nezhad, M. G., Jami, G., Kooshkaki, O., Chamani, S., & Naghizadeh, A. (2023) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2022.0185 · Cited by 25
Why and How Is Hyperferritinemic Sepsis Different From Sepsis Without Hyperferritinemia?*
Carcillo, J. A., Kernan, K. F., Horvat, C. M., Simon, D. W., & Aneja, R. K. (2020) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002285 · Cited by 24
Self-citation
Role of inflammasomes in acute respiratory distress syndrome
Flower, L., Vozza, E. G., Bryant, C. E., & Summers, C. (2025) · Thorax · doi:10.1136/thorax-2024-222596 · Cited by 26
Pre-Existing Cytokine and NLRP3 Inflammasome Activation and Increased Vascular Permeability in Diabetes: A Possible Fatal Link With Worst COVID-19 Infection Outcomes?
Lambadiari, V., Kousathana, F., Raptis, A. E., Katogiannis, K., Kokkinos, A. D., & Ikonomidis, I. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.557235 · Cited by 23
Antimicrobial stewardship and targeted therapies in the changing landscape of maternal sepsis
Shah, N. M., Charani, E., Ming, D. K. Y., Cheah, F., & Johnson, M. R. (2023) · Journal of Intensive Medicine · doi:10.1016/j.jointm.2023.07.006 · Cited by 25
Macrophage Activation Syndrome
Eloseily, E. M., & Cron, R. Q. (2018) · Springer eBooks · doi:10.1007/978-3-319-79026-8_14 · Cited by 26
Self-citation
Single versus combined immunoregulatory approach using PD-1 and CTLA-4 modulators in controlling sepsis
Rudick, C. P., Cornell, D. L., & Agrawal, D. K. (2017) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2017.1357469 · Cited by 22
Identification of human immune cell subtypes most responsive to IL-1β–induced inflammatory signaling using mass cytometry
Kothari, H., Williams, C. M., McSkimming, C. C., Drago, F., Marshall, M. A., Garmey, J. C., Vigneshwar, M., Zunder, E. R., & McNamara, C. A. (2021) · Science Signaling · doi:10.1126/scisignal.abc5763 · Cited by 22
COVID-19-associated secondary hemophagocytic lymphohistiocytosis (cytokine storm syndrome)
Alexeeva, E. I., Фаридович, Т. Р., Shilkrot, I. Y., Dvoryakovskaya, T. M., Surkov, A. G., & Kriulin, I. A. (2021) · Annals of the Russian academy of medical sciences · doi:10.15690/vramn1410 · Cited by 29
Continuous intravenous anakinra for treating severe secondary haemophagocytic lymphohistiocytosis/macrophage activation syndrome in critically ill children
Charlesworth, J. E. G., Wilson, S. R., Qureshi, A., Blanco, E., Mitchell, A. F., Segal, S., Kelly, D. F., Weitz, J., O'Shea, D., Bailey, K. M., et al. (2021) · Pediatric Blood & Cancer · doi:10.1002/pbc.29102 · Cited by 22
The critical role of neutrophil-endothelial cell interactions in sepsis: new synergistic approaches employing organ-on-chip, omics, immune cell phenotyping and in silico modeling to identify new therapeutics
Liu, D., Langston, J. C., Prabhakarpandian, B., Kiani, M. F., & Kilpatrick, L. E. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1274842 · Cited by 24
Safe usage of anakinra and dexamethasone to treat refractory hemophagocytic lymphohistiocytosis secondary to acute disseminated histoplasmosis in a patient with HIV/AIDS
Ocon, A. J., Bhatt, B. D., Miller, C. H., & Peredo-Wende, R. (2017) · BMJ Case Reports · doi:10.1136/bcr-2017-221264 · Cited by 22
Current treatment options and safety considerations when treating adult-onset Still’s disease
Cavalli, G., Farina, N., Campochiaro, C., Baldissera, E. M., & Dagna, L. (2020) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2020.1839411 · Cited by 22
The NLRP3 inflammasome is essential for IL-18 production in a murine model of macrophage activation syndrome
Gleeson, T. A., Kaiser, C., Lawrence, C. B., Brough, D., Allan, S. M., & Green, J. (2024) · Disease Models & Mechanisms · doi:10.1242/dmm.050762 · Cited by 20
Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment
Jang, J. H., Choi, E., Kim, T., Yeo, H. J., Jeon, D., Kim, Y. S., & Cho, W. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137396 · Cited by 21
Monocyte-macrophage membrane expression of IL-1R2 is a severity biomarker in sepsis
Supino, D., Davoudian, S., Silva-Gomes, R., Piovani, D., Garuti, R., Desai, A., Mapelli, S. N., Scavello, F., Carnevale, S., Mariancini, A., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07597-x · Cited by 21
The Interleukin Network in Sepsis: From Cytokine Storm to Clinical Applications
Candelli, M., Fernandez, M. S., Rozzi, G., Sodero, G., Piccioni, A., Pignataro, G., Rigante, D., & Franceschi, F. (2025) · Diagnostics · doi:10.3390/diagnostics15222927 · Cited by 25
Advances in CAR T Therapy for Hematologic Malignancies
Freyer, C. W., & Porter, D. L. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2414 · Cited by 21

Authors: Shakoory, B., Carcillo, J. A., Chatham, W. W., Amdur, R. L., Zhao, H., Dinarello, C. A., Cron, R. Q., & Opal, S. M.
Affiliations: George Washington University (US)
University of Pittsburgh Medical Center (US)
University of Alabama at Birmingham (US)
Temple University (US)
University of Colorado Anschutz (US)
Brown University (US)
ORCID: Shakoory, Bita
Carcillo, Joseph A.
Chatham, W. Winn
Amdur, Richard L.
Zhao, Huaqing
Dinarello, Charles A.
Venue: Critical Care Medicine
Publisher: Ovid Technologies (Wolters Kluwer Health)
Published: 2016-02
Volume: 44
Issue: 2
Pages: 275-281
ISSN: 0090-3493 (ISSN-L)
DOI: 10.1097/ccm.0000000000001402
PMC: PMC5378312
OpenAlex: W2177407033
Cited by: 867
References: 48
Citations by year: 2026: 66 · 2025: 64 · 2024: 68 · 2023: 76 · 2022: 87 · 2021: 141 · 2020: 226 · 2019: 43 · 2018: 36 · 2017: 42 · 2016: 15
FWCI: 24.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Locations: Critical Care Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institute of General Medical Sciences (R01GM108618)
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Health Sciences › Medicine › Hematology › Autoimmune and Inflammatory Disorders Research
Life Sciences › Immunology and Microbiology › Immunology › Inflammation biomarkers and pathways
Keywords: sepsis, anakinra, interleukin-1 receptor antagonist, interleukin-1 blockade, 28-day mortality, hepatobiliary dysfunction, disseminated intravascular coagulation, multiple organ failure, septic shock, subgroup analysis, hyperferritinemia, cytokine storm
MeSH terms: Adolescent, Adult, Age Factors, Aged, Aged, 80 and over, Biliary Tract Diseases, Disseminated Intravascular Coagulation, Double-Blind Method, Female, Humans, Liver Diseases, Male, Middle Aged, Multiple Organ Failure, Respiratory Distress Syndrome, Sex Factors, Shock, Septic, Receptors, Interleukin-1, Sepsis, APACHE, Interleukin 1 Receptor Antagonist Protein, Macrophage Activation Syndrome, Young Adult, Acute Kidney Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial*

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks